Citations

Clear

258 citation(s) found for "Ge, Tian".

Risk-adapted step-up local therapy for malignant portal vein tumor thrombus from hepatic metastases: A real-world study of microwave ablation with and without iodine-125 seed implantation.
Pham, Hoang Tran , Chun, Li, Bao, Weidong, Tian, Shichao, Zhao, Qingsong, Zhang, Mingyi , Yang, Z Y, Alba, Margarita De, Dong, Zhongyi , Parker, Jefferson , Morecroft, Renee, Elalfy, Aya, COTTLE, CHASEN, Ingram, Demarcus, Abdel-Hakeem, Ahmed, Bains, Shifali, Patel, Parth, Ali, Muhammad, Yang, Vivienne , Pham, Hoang Tran, Morecroft, Renée , Elalfy, Aya, Patel, Parth, Hartzell, Shannon

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 4235-4235

10.1200/jco.2026.44.16_suppl.4235 Get It

4235 Background: Malignant portal vein tumor thrombus (PVTT) arising from hepatic metastases is associated with poor prognosis, rapid hepatic decompensation, and limited effective local treatment options despite systemic therapy. In real-world practice, local treatment intensity is frequently adapted to disease burden and treatment response. We evaluated outcomes of a risk-adapted, step-up local treatment strategy using microwave ablation (MWA) alone or in combination with iodine-125 (I-125) seed implantation for patients with malignant PVTT. Methods: We retrospectively reviewed patients with hepatic metastases treated with MWA with or without I-125 seed implantation between 2023 and July 2025. In clinical practice, MWA alone was preferentially used for patients with relatively limited disease burden, while MWA plus I-125 was employed as an escalation strategy for patients with more advanced PVTT or disease progression following MWA alone. The primary endpoint was PVTT-directed local outcome, defined as portal vein patency and/or local control of tumor thrombus on follow-up imaging. Secondary endpoints included progression-free survival (PFS), overall survival (OS), hepatic function changes, and treatment-related toxicity. Survival analyses were considered exploratory. Results: A total of 73 patients were included, of whom 50 were treated with MWA alone and 23 with MWA plus I-125 seed implantation. Patients receiving MWA plus I-125 demonstrated more advanced disease characteristics, including universal presence of PVTT and higher disease stage, consistent with treatment escalation by disease severity. Among patients with PVTT, MWA plus I-125 achieved portal vein patency and/or local control in 65% at first follow-up imaging. Treatment-related toxicities were manageable, with no unexpected grade ≥3 adverse events attributable to I-125 implantation. Median PFS was 11.5 months in patients treated with MWA alone and 9.9 months in patients treated with MWA plus I-125, consistent with greater baseline disease burden in the latter group. Conclusions: MWA alone and MWA plus I-125 function as complementary components of a risk-adapted, step-up local treatment strategy for malignant PVTT from hepatic metastases. Escalation to MWA plus I-125 appears feasible in patients with advanced or refractory PVTT and demonstrates a potential signal for improved PVTT-directed local control and portal vein patency. Prospective studies focused on PVTT-specific endpoints are warranted.
Association of baseline quality of life (QOL) and early death in patients with metastatic renal cell carcinoma (mRCC) in the real-world prospective observational ODYSSEY study.
Ged, Yasser, Maughan, Benjamin L., Bhavsar, Nrupen Anjan, Costello, Brian A. , Kilari, Deepak , Gupta, Sorab , Bratton, Melyssa, Monk, Paul, Vaishampayan, Ulka N., Rose, Tracy L., Jabusch, Sarah, Ward, Kimberly T., Wu, Yuan, PAGE, COURTNEY, Zhang, Tian, George, Daniel J., Group, ODYSSEY Study, Vaishampayan, Ulka N. , Vaishampayan, Ulka , Harrison, Michael R. , Wulff, Elizabeth, Ged, Yasser , Maughan, Benjamin L. , Bhavsar, Nrupen Anjan , Appleman, Leonard J. , Zakharia, Yousef , Bratton, Melyssa R. , Monk, Paul , Rose, Tracy L. , Jabusch, Sarah , Ward, Kimberly T., Page, Courtney B , Zhang, T., George, Daniel J.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 4559-4559

10.1200/jco.2026.44.16_suppl.4559 Get It

4559 Background: Baseline QOL has been linked to survival in mRCC therapy clinical trials (Cella, 2024); however, there is a paucity of prospectively collected real-world QOL data across front-line management strategies. We used data from ODYSSEY to examine the relationship between baseline QOL and early death. Methods: ODYSSEY is a multi-site, prospective observational study of 468 US pts with mRCC. Pts must have mRCC (any histology); have no prior systemic therapy (ST) or be within 3 months of starting ST; and follow up at a PCORnet study site. Exclusion criteria include treatment for cancer except mRCC. The primary objective is to determine patterns of change in QOL and symptom burden of pts with mRCC. Early death was defined as death within 12 months post-enrollment. All pts with non-missing FKSI-19 or FKSI-DRS at enrollment were included. Cumulative event probabilities as a function of time were stratified by either < or ≥ median QoL value and plotted as a step function vs time since enrollment to create cumulative event curves. To determine association between QoL at enrollment and early death, separate Cox proportional hazards models (unadjusted and adjusted) for time-to-first-event as a function of baseline QoL were fit. The adjusted model controlled for the following baseline covariates: IMDC risk (favorable vs intermediate or poor), histology (clear cell vs non). Results: As of 1/5/26, 468 pts were enrolled; 425 had non-missing FKSI-19 or FKSI-DRS at enrollment (329 immediate ST, 96 deferred ST [DST]). ST included 129 IO-IO, 108 IO-TKI, 92 Other. DST included 57 Active Surveillance, 22 Local Therapy Planned, 17 Other/Missing. 209 and 190 pts have < median FKSI-19 (score = 59) and FKSI-DRS (score = 29), respectively; 216 and 235 pts have ≥ median FKSI-19 and FKSI-DRS, respectively. Those below the median have lower rates of nephrectomy, worse IMDC risk and KPS, shorter time since RCC diagnosis, and higher rates of bone metastasis (all p<0.05). Cumulative event probabilities for death at 12 months are 21% and 7% in those < and ≥ median baseline FKSI-19, respectively; and 21% and 7% in those < and ≥ median baseline FKSI-DRS, respectively. For FKSI-19, the unadjusted hazard ratio (HR) for early death is 0.55 (95% CI: 0.43 – 0.70; p<0.001) and adjusted HR is 0.65 (0.49 – 0.85; p = 0.002) per 1 SD higher score. For FKSI-DRS, the unadjusted HR for early death is 0.57 (95% CI: 0.46 – 0.71; p<0.001) and adjusted HR is 0.66 (0.51 – 0.86; p =0.002) per 1 SD higher score (higher score indicates better QOL). Conclusions: Across management strategies in our ODYSSEY cohort of systemic therapy naïve mRCC patients, better baseline QOL was associated with better survival. This is to our knowledge the largest reported real world mRCC cohort with prospectively collected PROs. Future analyses will focus on association of outcomes with longitudinal PROs. Clinical trial information: NCT04919122 .
Evaluating data extraction error by a large language model from randomised controlled trials: a large-scale empirical study
Fan, Shiqi , Chen, Ming, Doi, Suhail A , Ye, Zhangnan, Peng, Zhen, Tian, Yuan , Zhang, Chengzhi, Furuya-Kanamori, Luis, Lin, Lifeng, Mayo-Wilson, Evan, Murad, M Hassan, Meng, Xiuhong, Xu, Chang, Lin, Lifeng , Fan, Shiqi , Lin, Lifeng , Murad, M Hassan , Xu, Chang , Peng, Zhen, Furuya‐Kanamori, Luis , Mayo‐Wilson, Evan , Meng, Xiuhong

Mayo Clinic

BMJ Evidence-Based Medicine | April 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: bmjebm-2025-114044

10.1136/bmjebm-2025-114044 | PMID 42055792 Get It

Objective To examine the potential errors of a general large language model (LLM) (ie, Claude 3.5 Sonnet) on data extraction from randomised controlled trials (RCTs). Design and setting An empirical study comparing Claude 3.5 Sonnet extractions against a human-performed verification dataset. The extraction tasks for Claude 3.5 Sonnet were based solely on original RCT portable document format (PDF) files. For PDFs that could not be directly extracted by Claude 3.5 Sonnet, optical character recognition was employed to convert them into text format before extraction. Participants A random sample of 664 trials was selected from a well-established trial bank and a final data pool was established based on rigorous manual cross-checking as a reference standard. Data sources PubMed, EMBASE, Scopus, Web of Science (all databases) and the Cochrane Central Register of Controlled Trials (CENTRAL) up to February 2023. Eligibility criteria for selecting studies RCTs on children involving medication and adverse events. Main outcome measures Claude 3.5 Sonnet was applied to extract the basic information (eg, trial design, population information and source of funding) and adverse outcomes (ie, name of adverse events, number of events). Claude 3.5 Sonnet outputs were compared against the final data pool and all errors were recorded. Results are presented as error rates and with 95% CI, estimated using a generalised linear mixed model. Results For the 664 trials, a total of 23 069 data cells were extracted via Claude 3.5 Sonnet, with 10 624 for basic information and 12 445 for adverse outcomes. The overall error rate for data extraction was 6.6% (95% CI 5.4% to 8.2%), with 5.7% (95% CI 5.2% to 6.1%) in basic information and 7.6% (95% CI 4.9% to 11.8%) in adverse outcomes. When stratified the 1542 total errors by error types, misallocation (assigning data to incorrect fields; 57.1%, 881/1542) and missed or omitted data (incomplete extraction of available data; 23.2%, 357/1542) accounted for the two most frequent errors, with misallocation occurring more in basic information (53.3%, 470/881), while missed or omitted data occurred more in adverse outcomes (96.1%, 343/357). Post hoc analysis examining the association between trial reporting quality (assessed using Consolidated Standards of Reporting Trials (CONSORT) 2025 and LLM data extraction error rates indicated that higher CONSORT adherence was associated with lower extraction error rates. Conclusions The data extraction error of Claude was relatively low, but it alerts LLM applications in evidence synthesis. Detailed checking for LLM outputs should be the primary consideration for evidence synthesisers.
Artificial intelligence‐based statistical modeling delineates architectural distortion in focal cortical dysplasia
Cannon, Andrew , Tian, Roland, Ebner, Blake , Burkett, Brian J. , Gompel, Jamie Van, Hartley, Christopher P., Moreira, Roger K. , Raghunathan, Aditya, Gompel, Jamie J. Van , Burkett, Brian , Van Gompel, Jamie J , Wong-Kisiel, Lily C. , Watson, Robert E., Wong‐Kisiel, Lily C. , Hartley, Christopher P.

Mayo Clinic

Brain Pathology | March 26, 2026 | Volume: 36 | Issue: 5 | Pages: No page available

10.1111/bpa.70096 | PMID 42767799 Get It

Abstract In epilepsy patients lacking magnetic resonance imaging‐visible lesions such as focal cortical dysplasia (FCD), surgical resections target regions with abnormal electroencephalographic (EEG) activity. However, histopathological identification of subtle cortical architectural abnormalities in these specimens remains challenging. We investigated whether artificial intelligence (AI)‐based morphometric and spatial analysis of NeuN‐stained cortical sections could detect neuronal architectural disorganization in epilepsy resections, including regions without definitive histologic dysplasia. Whole slide images were generated from 83 FCD regions and 19 neurologically normal autopsy controls. Regions of interest were annotated in QuPath as FCD, FCD‐adjacent, FCD‐distant, apparently normal (abnormal EEG without histologic dysplasia), and true normal (autopsy controls). NeuN‐positive neurons were detected using QuPath (90% sensitivity, 12% false positive rate). Spatial and morphometric features—including neuronal clustering, distribution inhomogeneity, and nuclear morphology—were extracted and used to train a multinomial, Least Absolute Shrinkage and Selection Operator‐regularized regression classifier. The classifier achieved 70.6% accuracy in subregion classification and 88.2% accuracy in overall specimen diagnosis. Notably, regions with abnormal EEG but lacking histologic dysplasia exhibited quantifiable architectural disorganization similar to those seen in areas adjacent to FCD and distinct from control tissue. AI‐driven analysis of neuronal morphology and spatial distribution reveals subtle cortical disorganization in epilepsy resections, including in histologically ambiguous regions. Further investigation is warranted to determine if this methodology can enhance the diagnostic yield of neuropathological evaluation and support more precise surgical targeting in epilepsy.
VarStack2—an interactive web tool for somatic variant interpretation in cancer
Sreekumar, Nitin, Ahn, Benjamin J, Tian, Shulan , Uzun, Alper , Uzun, Ece D. Gamsiz , Gamsiz Uzun, Ece D

Mayo Clinic

Database | March 21, 2026 | Volume: 2026 | Issue: No issue available | Pages: No page available

10.1093/database/baag016 | PMID 41968112 Get It

Abstract The rapid progress in tumour genome sequencing has created a need for bioinformatics tools to interpret the clinical significance of detected variants. VarStack² integrates information from several publicly available resources, including the Catalogue of Somatic Mutations in Cancer (COSMIC), ClinVar, cBioPortal, UCSC Genome Browser, and ClinicalTrials.gov, CIViC and presents it through a user-friendly interface. VarStack2 simplifies the process of retrieving data, saving users significant time compared to manually navigating each database individually. Users can input a variant by specifying a gene symbol, amino acid change, and coding sequence change, with the option to search tumour-specific studies in cBioPortal alongside their primary query. Results are organized into separate sections and can be exported in CSV format for further analysis. Additionally, VarStack2 offers a smart search feature that suggests variants for the gene of interest based on its database search results. These features make VarStack2 a useful tool for scientists and clinicians by enhancing the variant interpretation process and integrating somatic variant information into workflows. VarStack² is freely available at http://varstack.brown.edu/
Epigenetically controlled endothelial promyelocytic leukemia drives liver inflammation and fibrosis
Gan, Can, Lai, Enjiang, Tai, Yang, Chen, Shuai, Zhao, Chong, Dai, Wenting , Yang, Zhu, Li, Bei , Lan, Tian, Xiao, Yang, Guo, Yangkun, Chen, Jiaxin , Wei, Bo, Cao, Sheng , Liu, Mengfei, Tacke, Frank, Tang, Chengwei, Shah, Vijay H. , Yu, Haopeng, Wang, Fei, Huang, Zhiyin , Gao, Jinhang, Gao, Jinhang , Gao, Jinhang , Lai, Enjiang, Tai, Yang, Lan, Tian, Xiao, Yang, Guo, Yangkun, Wei, Bo , Che, Zhaodi , Tacke, Frank , Tang, Chengwei , Yu, Haopeng

Mayo Clinic

Journal of Clinical Investigation | March 17, 2026 | Volume: 136 | Issue: 11 | Pages: No page available

10.1172/jci196730 | PMID 41842990 Get It

Cellular and molecular heterogeneity in the liver has been increasingly recognized to drive liver fibrosis progression, but the particular events that occur initially in response to liver injury and trigger immune cell recruitment remain unclear. Here, we identify epigenetically aberrant liver sinusoidal endothelial cells (LSECs) as key players in this process. Mechanistically, the epigenetic readers like bromodomain-containing protein 4–dependent (BRD4-dependent) super enhancers (SEs) activate proinflammatory genes, including promyelocytic leukemia (PML). The PML protein, in turn, binds BRD4 and amplifies proinflammatory angiocrine signaling through phase separation–dependent SE activation via PML/BRD4 condensate formation. In mouse models, LSEC-specific depletion of the PML/BRD4 complex mitigates liver inflammation and fibrosis. Single-cell RNA-seq reveals that epigenetically aberrant LSECs exhibit a reprogrammed proinflammatory angiocrine landscape in mouse fibrotic livers. TIMP1 + LSECs promote the recruitment of CD63 + monocyte–derived macrophages (MoMFs) during liver fibrosis progression. Thereby, PML/BRD4 in LSECs governs inflammatory immune cell recruitment in liver fibrosis. Pharmacological BRD4 inhibition or epigenetic PML-SE repression alleviates liver inflammation and fibrosis. In conclusion, PML/BRD4-mediated SE activation via phase separation drives proinflammatory angiocrine signaling in LSECs, initiating the inflammatory cascade and subsequent immune cell recruitment during liver fibrosis.
Structural insight into the CUB2 domain’s role in enteropeptidase-mediated trypsinogen activation
Song, Qiuyue, Peng, Lisi , Yang, Xia , Xu, Jiaheng , Zhang, Deyu , Tian, Xiaorong, Li, Shiyu , Ji, Baoan , Jin, Zhendong, Ding, Zhanyu , Li, Zhaoshen , Huang, Haojie, Huang, Haojie , Song, Qiuyue , Li, Shiyu, Zhang, Yu , Li, Zhaoshen , Huang, Haojie

Mayo Clinic

Proceedings of the National Academy of Sciences | March 16, 2026 | Volume: 123 | Issue: 12 | Pages: No page available

10.1073/pnas.2521394123 | PMID 41838910 Get It

Elucidating the structure and function of enteropeptidase (EP) is essential for advancing our understanding of its biological significance, particularly in regulating trypsinogen activation. Using cryo-EM and enzymatic activity, we uncovered the significance of the CUB2 domain in mediating the cleavage of macromolecular substrates. We identified crucial binding loops and key residues for EP’s proteolytic function. The mutation E574A enhanced the proteolytic activity of EP, whereas the mutation N619A diminished its cleavage efficiency, highlighting the importance of surface-charged interactions in modulating EP’s activity. A proteolytic cycle was proposed to deepen our understanding of the trypsinogen activation by EP. This work offers valuable insights into the molecular mechanisms underlying EP’s interaction with its substrate, and opens up avenues for therapeutically modulating EP-mediated proteolysis.
In Vivo Selection of anti-glioblastoma DNA aptamer-drug conjugates in an orthotopic patient-derived xenograft model
Wilbanks, Brandon , Wilbanks, Brandon A , III, Louis James Maher , Doherty, Caroline , Jain, Sonia , Ott, Lauren L. , Bakken, Katie, Burgenske, Danielle M. , Pearson, Keenan , Griffith, Jessica I. , Tian, Zichen, Meridew, Jeffrey A., Yerneni, Saigopalakrishna S. , Elmquist, William F. , Sarkaria, Jann N.

Mayo Clinic

No container title available | February 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.16.706148 | PMID 41756849 Get It

Abstract Glioblastoma (GBM) is an aggressive, high-grade glioma with a near-universally fatal prognosis. Therapeutic failure is often attributed to the highly selective blood brain barrier (BBB), the diffuse infiltrative nature of the tumor, and the marked intratumoral heterogeneity of GBM. Although antibody drug conjugates ADCs have shown promise for high grade gliomas such as GBM, efficacy is limited by ADC size. Aptamers—short, synthetic, single-stranded DNA or RNA molecules—can be ∼6-fold lower in molecular weight than IgG antibodies and have the potential to cross the intact BBB. Unlike other nucleic acid-based therapies, aptamer function arises from three-dimensional shape rather than genetic coding. Here we aim to replace the targeting component of the ADC paradigm with a DNA aptamer, thus creating an aptamer-drug conjugate (ApDC). We employed in vivo SELEX using an orthotopic patient-derived xenograft (PDX) GBM mouse model and a vast (∼100 trillion 80-mer sequences) ApDC library. We report the results from this first in vivo ApDC selection of its kind. We characterize target tissue binding ex vivo , cell association, biodistribution, and pharmacokinetics from this selection. This study exemplifies an unbiased approach to a problem that rational design has yet to overcome, offering a new direction for GBM therapeutic development.
Outcomes of Minimally Interrupted versus Uninterrupted Direct Oral Anticoagulants Use Prior to Implantation of Cardiac Implantable Electronic Devices
Dai, Qiying , Khan, Hina Rmsha Alfia, Zou, Tian , Wang, Weijia, Tian, Zou, Wang, Weijia , Liu, Xiaoke

Mayo Clinic

Journal of Cardiovascular Electrophysiology | February 18, 2026 | Volume: 37 | Issue: 4 | Pages: 864-868

10.1111/jce.70289 | PMID 41703896 Get It

ABSTRACT Background Optimal management of direct oral anticoagulants (DOAC) prior to implantation of cardiac implantable electronic devices (CIED) remains controversial. Objective To determine whether a strategy of minimal interruption of DOAC before cardiac CIED implantation is associated with improved clinical outcomes compared to uninterrupted DOAC use. Methods The electronic clinical records of 310 patients who were on DOAC and underwent CIED implantation were evaluated. The patients were separated into 2 groups: patients in Group 1 had minimal DOAC interruption (DOAC held < 24 h before procedure), while patients in Group 2 continued DOAC before procedure. Resumption of DOAC in both groups was on the same day of the procedure or the next morning at the operator's discretion. Clinically significant pocket hematoma and thromboembolic events were compared. Results Among the 310 patients, 71 (22.9%) of them had DOAC held < 24 h before procedure, while DOAC was continued without interruption in 239 (77.1%) in the periprocedural period. Clinically significant pocket hematomas were found in 1 patient (1.4%) in the DOAC interrupted group and 24 (10.0%) in the DOAC continuous group ( p = 0.046). Low thromboembolic events were observed in both groups: 0 in the minimally interrupted group and 1 (0.4%) in the un‐interrupted group ( p > 0.05). Conclusion The bleeding risk in our cohort of patients who underwent CIED implantation with the uninterrupted DOAC approach is higher than previously reported in the literature. A minimally interrupted approach appears to mitigate this risk without significantly increasing the risk of thromboembolism.
Multi-model Diffusion MRI Signatures in Atypical Parkinsonian Disorders
Tian, Yuqi , Ali, Farwa, Machulda, Mary M., Josephs, Keith A, Whitwell, Jennifer, Machulda, Mary M. , Ali, Farwa , Machulda, Mary M , Josephs, Keith A , Whitwell, Jennifer , Ali, Farwa , Lowe, Val J. , Josephs, Keith A. , Whitwell, Jennifer L.

Mayo Clinic

No container title available | February 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.05.26345656 | PMID 41674642 Get It

Abstract Distinguishing atypical parkinsonian disorders (APS) from Parkinson’s disease (PD) remains challenging due to overlapping clinical features, yet accurate differentiation is critical for prognosis and treatment. Here, we employed multi-model diffusion MRI (dMRI) analysis to characterize microstructural alterations across corticobasal syndrome (CBS), progressive supranuclear palsy-Richardson syndrome (PSP-RS) and PD, with the aim of identifying which dMRI model provides optimum differentiation. We analyzed 25 CBS, 42 PSP-RS, and 21 PD participants compared to 35 age and sex-matched controls. Using a clinically feasible 3-shell high angular resolution diffusion imaging (HARDI) protocol, we applied 11 metrics from five complementary dMRI models—diffusion tensor imaging (DTI), free-water-eliminated model of DTI (FWE), neurite orientation dispersion and density imaging (NODDI), tissue-weighted NODDI, and Fixel Density (FD) in fixel-based analysis (FBA) —to comprehensively assess regional white and gray matter integrity. Group differentiation was assessed using Cohen’s d effect sizes and spearman correlations were assessed between dMRI metrics and clinical scales. Distinct microstructural signatures were observed across disorders and the sensitivity of the dMRI models differed. In group contrasts, DTI and NODDI-derived metrics consistently captured the strongest effects in midbrain and peduncular pathways for PSP-RS, whereas precentral and corticospinal alterations in CBS were most prominent using NODDI and FBA measures. Free-water-corrected metrics showed attenuated group differences. Across clinical-diffusion analyses, NODDI metrics exhibited the most robust associations with disease severity, while DTI and FWE measures detected more limited, regionally constrained effects. Together, these findings highlight complementary yet distinct sensitivities of tensor, free-water, multi-compartment, and fixel-based models to APS-related neurodegeneration.